A Phase 4 interventional study of Salmeterol/ fluticasone propionate in Asthma, sponsored by GlaxoSmithKline. Completed at 14 sites in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-11-12.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing Salmeterol Xinafoate in Asthma — none open to participants now, none under way, none of them phase 3. Salmeterol Xinafoate · Asthma.
Among the 46 studies testing Salmeterol Xinafoate in Asthma, this one is the 12th largest by enrollment, is one of 7 that started in 2004, is one of 26 in phase 4, and was the 23rd registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →None of the 46 studies testing Salmeterol Xinafoate in Asthma is open now. The open studies under Asthma, anywhere →
Salmeterol Xinafoate: first FDA approval 1994 (SEREVENT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 7 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 424 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 128 across the 46 interventional studies. Of the 43 that completed or were terminated, 17 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 46 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 54th largest by enrollment of the 238 interventional ones that give a count, is one of 10 that started in 2004, is one of 53 in phase 4, and was the 54th registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 46 studies testing Salmeterol Xinafoate in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
The primary study objective is to demonstrate the clinical effectiveness of SERETIDE therapy compared to the current care in management of moderate to severe persistent asthma patients in Korea.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SERETIDE 50/250
Drug: Salmeterol/ fluticasone propionate
SERETIDE 50/500
Drug: Salmeterol/ fluticasone propionate
Drug pages: Salmeterol Xinafoate · Fluticasone
2 active arms (parellel group)
Also known as: SERETIDE
The primary efficacy endpoint for this trial is mean morning PEFR LOCF at 52 weeks as collected in diary cards over the last 2 weeks preceding the 52 weeks visit.
Time frame: 52 weeks after randomization
Secondary measures of efficacy consist of clinical efficacy and health outcome measurements.
Time frame: 52 weeks after randomization
The record gives a start of Jan 2004, a primary completion of Sep 2005 and a completion of Sep 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Salmeterol Xinafoate · Fluticasone